Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of
recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin
Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when
administered with paclitaxel, carboplatin and erlotinib.
Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the
treatment of advanced non-small cell lung cancer